Talphera (NASDAQ:TLPH) Share Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Shares of Talphera, Inc. (NASDAQ:TLPH – Get Free Report) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $1.01 and traded as low as $0.77. Talphera shares last traded at $0.9060, with a volume of 1,219,659 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of Talphera in a research report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a research report on Thursday, October 15th. Finally, Wall Street Zen raised Talphera to a “hold” rating in a research note on Saturday, August 8th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $3.00.

Get Our Latest Research Report on Talphera

Talphera Stock Performance

The business has a 50-day simple moving average of $1.11 and a 200 day simple moving average of $1.01. The firm has a market cap of $47.03 million, a P/E ratio of -4.31 and a beta of 0.77.

Talphera (NASDAQ:TLPH – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). On average, research analysts expect that Talphera, Inc. will post -0.23 EPS for the current year.

About Talphera

(Get Free Report)

Talphera, Inc., formerly known as AcelRx Pharmaceuticals, is a specialty pharmaceutical company focused on developing and commercializing treatments for acute pain and critical care. The company’s portfolio includes DSUVIA, a sublingual formulation of sufentanil for the management of acute pain in adults in medically supervised settings. Talphera is also developing Niyad, a nafamostat-based anticoagulant intended for use in extracorporeal circuits during continuous renal replacement therapy. The company’s work in this area is aimed at addressing treatment needs in critical care settings.

Read More

Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.